Mankind Pharma’s Q3 FY25 net profit declined 16% YoY to ₹385 crore despite a 24% revenue increase to ₹3,230 crore. Domestic revenues rose 17%, exports more than doubled, and consumer health grew 30%.
Stock-specific action to dominate market moves: Dharmesh Shah
Dharmesh Shah suggests focusing on the domestic sector, with banking showing relative outperformance even in the current corrective phase. He advises positive stances on banking,